Actively Recruiting
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts
Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-03-02
368
Participants Needed
13
Research Sites
443 weeks
Total Duration
On this page
Sponsors
F
Fondation Ophtalmologique Adolphe de Rothschild
Lead Sponsor
M
Ministry of Health, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.
CONDITIONS
Official Title
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Isolated large artery blockage in the front brain circulation confirmed by CTA or MRA
- Stroke symptoms started less than 24 hours before imaging
- Eligible for mechanical thrombectomy with specific brain imaging criteria showing a significant ischemic penumbra
- Pre-stroke disability score (mRS) of 2 or less
- Stroke severity score (NIHSS) of 6 or more
You will not qualify if you...
- Contraindication to mechanical thrombectomy
- Age over 80 with more than 10 microbleeds on MRI before treatment
- Pre-existing dependency with mRS of 3 or higher
- Known tandem ICA-MCA occlusions requiring stenting
- ASPECT score less than 6 on brain CT or MRI
- Known allergy to cangrelor or its components (mannitol, sorbitol)
- History of previous brain hemorrhage
- Active bleeding or recent trauma
- Recent surgery with high bleeding risk
- Taking vitamin K antagonists with INR over 1.7
- Recent use of blood thinners such as heparin or DOACs with certain blood levels
- Low platelet count below 100,000 per mm3
- Woman of childbearing age without a negative pregnancy test
- Under legal protection
- Not covered by a national insurance scheme
- Patient or trusted person opposes participation
- Participation in another acute ischemic stroke study that conflicts with this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
CHU de Besançon
Besançon, France, 25030
Actively Recruiting
2
Hôpital Pellegrin (CHU de Bordeaux)
Bordeaux, France
Actively Recruiting
3
Hospices civils de Lyon, Hôpital Pierre Wertheimer
Bron, France, 69500
Actively Recruiting
4
Hôpital Salengro (CHU Lille)
Lille, France, 59037
Actively Recruiting
5
Hôpital Dupuytren (CHU Limoges)
Limoges, France, 87000
Actively Recruiting
6
CHU La Timone
Marseille, France, 13005
Actively Recruiting
7
Hôpital Central (CHU de Nancy)
Nancy, France, 54000
Actively Recruiting
8
Hôpital Lariboisière AP-HP
Paris, France, 75010
Actively Recruiting
9
Hôpital Pitié-Salpêtrière AP-HP
Paris, France, 75013
Actively Recruiting
10
Hôpital Fondation A de Rothschild
Paris, France, 75019
Actively Recruiting
11
CHU de Strasbourg
Strasbourg, France, 67200
Actively Recruiting
12
Hôpital Foch
Suresnes, France, 92150
Actively Recruiting
13
Hôpital Purpan (CHU de Toulouse)
Toulouse, France, 31300
Actively Recruiting
Research Team
M
Mikael Pr MAZIGHI, Pr
CONTACT
A
Amélie YAVCHITZ, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here